Lisata Therapeutics (LSTA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants John Menditto - Vice President of Investor Relations & Corporate CommunicationsDavid Mazzo - President and Chief Executive OfficerJames Nisco - SVP of Finance, Treasurer, CAO & Principal Financial & Accounting OfficerKristen Buck - EVP of R&D and Chief Medical OfficerSara Nik - Senior Associate - Equity ResearchPeter Enderlin - Portfolio Manager Conference Call Participants Kemp Dolliver - Director - Research & Se ...

Fox Factory (FOXF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Toby Merchant - Chief Legal Officer, Chief Compliance Officer & SecretaryMichael Dennison - CEO & DirectorDennis Schemm - President of AAG & CFOJames Duffy - Managing DirectorPeter Lukas - DirectorMichael Swartz - Director - Equity ResearchBret Jordan - Managing Director Conference Call Participants Anna Glaessgen - Senior Analyst, ConsumerScott Stember - Executive Director & Senior Research Analyst Operator Good afternoo ...

Alarm.com (ALRM) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Matthew Zartman - Vice President of Strategic Communications & Investor RelationsStephen Trundle - President & CEOKevin Bradley - CFOMatt Bullock - Equity Research AssociateAdam Tindle - Managing DirectorSaket Kalia - Managing DirectorBilly Fitzsimmons - VP - Equity ResearchMatthew Filek - Equity Research Associate Conference Call Participants Darren Aftahi - Senior Research Analyst-Internet, Media and Enabling Technologies ...

The Beauty Health Company (SKIN) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Norberto Aja - Investor RelationsMarla Beck - President & CEOMichael Monahan - CFOJonathan Block - Managing DirectorSarah Whitaker Clemente - Director, Healthcare Conference Call Participants None - AnalystSusan Anderson - Managing Director & Senior AnalystBruce Jackson - Senior AnalystNavann Ty - Analyst Operator and welcome to today's Beauty Health Company First Quarter twenty twenty five Earnings Call. At ...

Financial Data and Key Metrics Changes - Revenue for the first quarter increased by 67% compared to the same period in the prior year, reaching $18.5 million [6][25] - Gross profit margin for the first quarter was 84.7%, down from 86.4% in the same period of 2024 [26] - Net loss for the first quarter was $13.9 million, improving from a net loss of $18.7 million in the same period in 2024 [30] Business Line Data and Key Metrics Changes - The launch of ReCell Go Mini and Co Helix is expected to significantly contribute to revenue growth throughout 2025 [25][32] - The commercial lineup now includes ReCell, ReCell Go, ReCell Go Mini, Co Helix, and Permeoderm, providing a broad spectrum of products for both burn and trauma centers [14][15] Market Data and Key Metrics Changes - The US addressable market for the company has expanded from approximately $500 million to over $3.5 billion annually, marking a seven-fold increase [6][22] - The trauma market is estimated to have approximately 270,000 cases annually in the US, which ReCell Go Mini targets [10] Company Strategy and Development Direction - The company is focusing on acute wound care, stepping back from further commercial investment in the vitiligo indication due to uncertainty in reimbursement [21][56] - A significant shift in the commercial model has been implemented, transitioning from a service-oriented approach to a more focused selling-oriented approach [16][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for strong results driven by the expanded product portfolio and operational efficiencies [22][32] - The company expects to generate free cash flow in the second half of the year and achieve GAAP profitability in Q4 of 2025 [31][32] Other Important Information - The company has secured a waiver for its first-quarter trailing twelve-month revenue covenant with OrbiMed, which had been set at $73 million [31] - The annual meeting of stockholders is scheduled for June 4 [32] Q&A Session Summary Question: Can you share any response or performance impressions of Co Helix? - Management noted that early feedback has been positive, with a case from Ohio State demonstrating a seven-day graft readiness, which is faster than other dermal matrices [36][37] Question: How is the rollout of ReCell Go Mini going? - The response has been good, particularly from existing accounts in the trauma area, with opportunities to provide more value to trauma surgeons [41][42] Question: What are the expected revenue contributions from the new launches? - Management indicated that while they are not ready to provide specific guidance, they expect these products to be material contributors to revenue [45] Question: Is the sales force adequately staffed to meet revenue targets? - Management expressed confidence in the current staffing levels and the reconfigured sales model, which focuses on a selling-oriented approach [47][49] Question: What is the expected revenue cadence for the rest of the year? - Management anticipates steady sequential growth throughout the year, with some weighting towards the back end as new products gain traction [51][52] Question: What is the current status of the vitiligo initiative? - The company has paused spending on vitiligo due to uncertainty in reimbursement and is focusing resources on acute wound care instead [56][58]

GrowGeneration (GRWG) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Philip Carlson - Managing DirectorDarren Lampert - CEO and Co-FounderGreg Sanders - Chief Financial OfficerAaron Grey - Managing Director, Head of Consumer Research Conference Call Participants Mark Smith - Senior Research AnalystBrian Nagel - MD & Senior Analyst - Consumer Growth & eCommerce Operator Hello, everyone, and welcome to GrowGeneration's First Quarter twenty twenty five Earnings Conference Call. My name is ...

Financial Data and Key Metrics Changes - Revenue for Q1 was $598 million, reflecting a slight decline of 0.8% year-over-year on a constant currency basis, primarily due to softer enabling technology sales and supply chain disruptions [6][19] - Non-GAAP EPS increased by 9% to $0.68 compared to the prior year, despite a higher diluted share count and a one-time EPS gain not repeated in 2025 [6][20] - Free cash flow reached a record $141 million, up 493% from the previous year, with the company returning to debt-free status after paying off nearly $900 million from the NuVasive merger [7][30] - GAAP net income was $75.5 million, translating to fully diluted GAAP earnings of $0.54 per share, an increase from the prior year quarter [20] Business Line Data and Key Metrics Changes - U.S. Spine revenue grew by 2% in Q1, driven by strong retention rates and product cross-selling, despite temporary supply chain disruptions [8][21] - Enabling Technologies revenue decreased by 31% to $22 million, impacted by a tough prior year comparison and elongated selling cycles [12][19] - The combined trauma and NSO business declined by 8%, although core trauma delivered 34% growth [14][21] - International spine implant business grew by 1% on a constant currency basis, affected by timing of distributor orders and supply chain issues [13][21] Market Data and Key Metrics Changes - U.S. revenue was $483.9 million, essentially flat compared to the prior year, while international revenue decreased by 7.7% [26] - The overall market growth was described as slow, with surgeons noting longer approval times from insurance companies [95] Company Strategy and Development Direction - The company aims to focus on sustained profitable growth, leveraging financial strength to accelerate top-line results while maintaining strong EPS and free cash flow [7][8] - The acquisition of Nevro for $250 million is expected to expand the company's reach into the musculoskeletal market, adding a $3 billion market space [14][15] - The company is committed to integrating Nevro into its existing infrastructure to improve profitability and cash flow [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from Q1 challenges, citing positive trends in U.S. Spine and ongoing remediation of supply chain issues [45][46] - The company reaffirmed its 2025 net sales guidance of $2.8 billion to $2.9 billion but lowered non-GAAP EPS guidance to $3.0 to $3.3 due to additional costs from the Nevro acquisition [36][37] - Management remains optimistic about the second quarter, expecting to see improved results as supply chain disruptions ease [37][38] Other Important Information - The company has completed its share repurchase program, buying back over 20% of the dilution created from the NuVasive merger [30][31] - The company is actively addressing tariff impacts through cost action offsets, including price increases and vendor negotiations [35][112] Q&A Session Summary Question: Confidence in Q2 performance after a challenging Q1 - Management indicated that supply chain disruptions and timing of distributor orders were temporary issues, with confidence in a recovery in Q2 [45][46] Question: Synergies from the Nevro acquisition - Focus will be on reducing operational expenses and improving gross margins, with a commitment to driving profitable sales growth [48][49] Question: Impact of competitors on sales cycles - Management noted that while selling cycles have elongated, they have not seen competitors causing delays in closing deals [53][54] Question: Expectations for cash use post-Nevro acquisition - The company plans to prioritize internal investments and may consider tuck-in acquisitions, with share repurchases remaining part of the capital structure [62][64] Question: Integration status of Nevro and NuVasive - Management reassured that Nevro's integration is separate from ongoing NuVasive activities, with confidence in managing both integrations effectively [86][88] Question: Update on FDA warning letter - Management reported progress with the FDA and is awaiting inspection, expressing readiness to resolve the matter [92] Question: Impact of tariffs on margins - Management stated that tariffs are not expected to materially impact margins due to the company's vertical integration and U.S.-based production [111][112]

Financial Data and Key Metrics Changes - For Q1 2025, the company's commercial revenue was $18.5 million, representing a 67% increase compared to the same period in 2024 [24] - The gross profit margin for Q1 was 84.7%, down from 86.4% in the same period of 2024, primarily due to volume discounts and product mix [25] - The net loss for Q1 was $13.9 million, improving from a net loss of $18.7 million in the same period in 2024 [28] Business Line Data and Key Metrics Changes - The launch of ReCell Go Mini and Co Helix is expected to significantly contribute to revenue growth throughout 2025 [24][30] - The company has expanded its product portfolio to include ReCell Go, ReCell Go Mini, Co Helix, and Permuderm, targeting both burn and trauma centers [13][21] Market Data and Key Metrics Changes - The US addressable market for the company has expanded from approximately $500 million to over $3.5 billion annually, marking a seven-fold increase [5] - The trauma market is estimated to have approximately 270,000 cases annually in the US, which the new ReCell Go Mini product aims to address [8] Company Strategy and Development Direction - The company is focusing on acute wound care, stepping back from further commercial investment in the vitiligo indication due to uncertainty in reimbursement [20][52] - A significant shift in the commercial model has been implemented, moving from a service-oriented approach to a more focused selling-oriented approach [15][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting to generate free cash flow in the second half of the year and achieve GAAP profitability in Q4 2025 [29][30] - The company is actively engaged in the public comment process for a proposed new technology add-on payment for ReCell, which could take effect on October 1 [20] Other Important Information - The company expects to save approximately $2.5 million per quarter in operating expenses due to recent transformations and operational efficiencies [27][29] - The annual meeting of stockholders is scheduled for June 4, encouraging participation [30] Q&A Session Summary Question: Response and performance of Co Helix during limited commercial launch - Management noted that early feedback from the limited market release of Co Helix was positive, with a notable case demonstrating faster graft readiness compared to other dermal matrices [33][34] Question: Revenue contributions from ReCell Go Mini - Management indicated that ReCell Go Mini is expected to be a material contributor to revenue, with plans to break out non-resale sales by Q3 [41][42] Question: Sales force adequacy to meet revenue targets - Management expressed confidence in the current sales force structure, which has been reconfigured to enhance selling capabilities across the product portfolio [43][46] Question: Revenue cadence expectations for the rest of the year - Management expects steady sequential growth throughout the year, with some weighting towards the back end as new product approvals are anticipated [48][49] Question: Status of the vitiligo initiative and reimbursement discussions - Management clarified that spending on the vitiligo initiative has been paused due to uncertainty in achieving reimbursement, focusing resources on acute wound care instead [52][53]

Senseonics (SENS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Please stand by. Your program is about to begin. Good day, everyone, and welcome to the Senseonics First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask questions by pressing the star and one on your telephone keypad. You may withdraw your question by pressing star, t ...

Expedia Group (EXPE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the Expedia Group Q1 twenty twenty five Financial Results Teleconference. My name is Alex, and I'll be the operator for today's call. For opening remarks, I will turn the call over to SVP, Corporate Development, Strategy and Investor Relations, Harshita Ash to begin. Please go ahead. Speaker1 Good afternoon and welcome to Expedia Group's first quarter twenty twenty five earnings call. I'm pleased ...